Oncology dealmaking fell sharply in 2024, with total cancer-focused licensing and M&A activity dropping about 50% from 2023. The article includes data in part from DealForma, highlighting a shift toward broader tumor-type therapies and popular modalities like ADCs, radioligand therapies, and multi-specific antibodies. Read the article here
